Cudetaxestat

Overview

Cudetaxestat (BLD-0409; PAT-409) is an orally active and noncompetitive autotaxin (ATX) inhibitor. Cudetaxestat inhibits the activity of ATX , reduces the production of LPA , and thereby blocks the signal transduction of the ATX-LPA axis. Cudetaxestat can still maintain nanomolar-level biochemical efficacy even when the concentration of the LPC substrate increases. Cudetaxestat can be used for the study of various diseases related to LPA including fibrosis, tumor metastasis, inflammation and autoimmune diseases, etc.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Phosphodiesterase (PDE) | Products > Signaling Pathways > LPL Receptor

Product Information

• Catalog No.: HY-145561
• CAS No.: 1782070-21-6
• Molecular Formula: C21H15Cl2F2N3O2S
• Molecular Weight: 482.33
• Purity: 98.32%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (4.31 mM); Clear solution
• Availability: In-stock

Source

Original product source